Abstract

e15507Background: Liquid biopsy is an alternative to tissue biopsy for biomarker testing. In addition, it can be used to monitor the response to therapy and the molecular evolution of the disease. ...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
540P - Analysis of liquid biopsies from metastatic colorectal carcinoma (mCRC) patients (pts) enrolled in the CAPRI GOIM clinical trial
...
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 28
, et. al. ...
01 Sep 2017
Does serum VEGF predict prognosis in metastatic colorectal carcinoma patients treated with XELIRI?
H S Bozcuk ... T Ozben
Journal of Clinical Oncology | VOL. 24
H S Bozcuk, et. al.H S Bozcuk ... T Ozben
20 Jun 2006
Resistance to immune checkpoint inhibitors in colorectal cancer with deficient mismatch repair/microsatellite instability: misdiagnosis, pseudoprogression and/or tumor heterogeneity?
Nicola Normanno ... Fortunato Ciardiello
Exploration of targeted anti-tumor therapy | VOL. 5
Nicola Normanno, et. al.Nicola Normanno ... Fortunato Ciardiello
23 May 2024
RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial
...
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 29
, et. al. ...
01 Jan 2018
View more papers

More From: Journal of Clinical Oncology

Paper Title
Journal
Date
Author
Genetic Counseling, Testing, and Family Communication Into Survivorship After Diagnosis of Breast Cancer.
Steven J Katz ... Allison W Kurian
Journal of Clinical Oncology | VOL. -
Steven J Katz, et. al.Steven J Katz ... Allison W Kurian
15 Jul 2024
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY.
Yoon-Koo Kang ... Sung Hoon Noh
Journal of Clinical Oncology | VOL. -
Yoon-Koo Kang, et. al.Yoon-Koo Kang ... Sung Hoon Noh
12 Jul 2024
Individualized Local Recurrence Estimates for Ductal Carcinoma In Situ.
Laura E G Warren ... Jennifer R Bellon
Journal of Clinical Oncology | VOL. -
Laura E G Warren, et. al.Laura E G Warren ... Jennifer R Bellon
11 Jul 2024
Are Oral Selective Estrogen Receptor Degraders Beneficial for Patients With ESR1-Mutated Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer?
Aoba Okeya ... Chikako Shimizu
Journal of Clinical Oncology | VOL. -
Aoba Okeya, et. al.Aoba Okeya ... Chikako Shimizu
11 Jul 2024
View more papers